Hongru Li | Brain Metastasis | Best Researcher Award

Dr. Hongru Li | Brain Metastasis | Best Researcher Award

Fuzhou University Affiliated Provincial Hospital | China

Dr. Hongru Li, MD/PhD, is a distinguished clinician-scientist and Chief Physician in the Department of Respiratory and Critical Care Medicine at Fujian Provincial Hospital, Fujian Medical University. With a career dedicated to advancing respiratory medicine and oncology, his expertise lies in lung cancer, metastasis mechanisms, and innovative therapeutic strategies. Over the years, he has combined clinical excellence with groundbreaking research, focusing on molecular pathways and targeted therapies. Dr. Li has published extensively in reputable journals, contributing to understanding brain and bone metastasis in non-small cell lung cancer. His leadership extends to supervising clinical innovation projects funded by national and provincial research grants. Recognized as an outstanding respiratory scholar, he has made notable contributions in translational medicine, bridging laboratory findings with patient care. His research on nanoliposomes, ceramide pathways, and genetic susceptibility in lung cancer exemplifies his commitment to improving treatment outcomes and patient survival in respiratory oncology.

Profile

ORCID

Education

Dr. Hongru Li’s academic foundation is firmly rooted in medicine and specialized respiratory science. He earned his Doctor of Medicine degree at Fujian Medical University, where he developed his core clinical knowledge and interest in pulmonary health. To deepen his expertise, he pursued postgraduate studies in respiratory medicine at Fujian Medical University, gaining hands-on exposure to advanced diagnostic and therapeutic approaches in pulmonary and critical care. His academic journey culminated with a PhD in Respiratory Medicine from Southern Medical University in Guangzhou, where he focused on molecular mechanisms of lung cancer progression and metastasis. His doctoral research provided a solid grounding in translational medicine, integrating clinical insights with cellular and molecular biology. This comprehensive educational background has enabled him to pursue a career balancing patient care with high-impact research, positioning him as a leader in respiratory medicine, oncology, and translational research with a strong focus on innovation and clinical application.

Experience

Dr. Hongru Li has accumulated extensive clinical and academic experience at Fujian Provincial Hospital, where he has advanced through progressive leadership roles in respiratory and critical care medicine. Starting as a resident doctor, he gained experience in managing complex respiratory cases, developing proficiency in critical care interventions. He then served as an attending doctor, where he refined his clinical judgment and mentored junior staff. His expertise led to his appointment as Associate Chief Physician, where he oversaw specialized clinical programs and research initiatives. Currently, as Chief Physician, Dr. Li leads the Department of Respiratory and Critical Care Medicine, managing advanced patient care, research collaborations, and clinical training. His responsibilities span from clinical decision-making to developing research projects funded by provincial and national agencies. With deep involvement in translational research, he bridges laboratory discoveries with real-world patient care, positioning him as both a skilled clinician and an innovative medical researcher.

Awards and Honors

Dr. Hongru Li has been recognized for his exceptional contributions to clinical medicine, research innovation, and academic excellence. Early in his career, he received the Excellent Graduate Award and Excellent Postgraduate Award from Fujian Medical University, reflecting his academic dedication and professional promise. His trajectory of excellence was further reinforced with the prestigious Outstanding Youth Respiratory Scholar Award for Clinical Innovation in China, acknowledging his groundbreaking research and leadership in respiratory medicine. These honors underscore his commitment to advancing lung cancer research, patient care, and translational medicine. His ability to secure competitive research funding and lead innovative studies further reflects his recognition as a trusted expert in his field. In addition, his patents and numerous peer-reviewed publications highlight the impact of his scientific contributions. These accolades collectively demonstrate not only his academic excellence but also his role as a leading physician-researcher shaping the future of respiratory and oncology medicine.

Research Focus

Dr. Hongru Li’s research centers on the molecular mechanisms driving lung cancer progression and metastasis, with particular emphasis on brain and bone metastases in non-small cell lung cancer. He explores signaling pathways, genetic susceptibility, and the role of lipids and ceramide metabolism in tumor development. His studies have investigated proteins such as livin, RPTOR, and ceramide synthase in regulating tumor proliferation, apoptosis, and metastatic spread. Through innovative approaches, including nanoliposome-based therapies, he seeks to inhibit cancer metastasis and improve treatment responses. He has also examined genetic polymorphisms and signaling cascades, such as the PI3K/AKT/mTOR and Wnt pathways, to understand cancer susceptibility and therapy resistance. His translational research aims to transform laboratory findings into clinical applications, offering new diagnostic biomarkers and therapeutic targets. Supported by national and provincial grants, his work significantly contributes to advancing precision medicine, improving survival, and developing novel treatment strategies for patients with lung cancer.

 

Publications

 

Title: KLF9 Inhibits Brain Metastasis of Non‐Small Cell Lung Cancer by Regulating Ceramide Synthase 1 Synthesis
Year: 2025

Title: Efficacy of Prophylactic Cranial Irradiation in Early to Mid-stage Small Cell Lung Cancer Patients in the Era of Magnetic Resonance Imaging
Year: 2024

Title: Development and validation of a nomogram model based on blood-based genomic mutation signature for predicting the risk of brain metastases in non-small cell lung cancer
Year: 2024

Title: Antibacterial effect of phage cocktails and phage-antibiotic synergy against pathogenic Klebsiella pneumoniae
Year: 2024

Title: Clinical application value of metagenome next-generation sequencing in pulmonary diffuse exudative lesions: a retrospective study
Year: 2024

Title: Successful treatment of severe lung cancer caused by third-generation EGFR-TKI resistance due to EGFR genotype conversion with afatinib plus anlotinib
Year: 2024

Title: RPTOR blockade suppresses brain metastases of NSCLC by interfering the ceramide metabolism via hijacking YY1 binding
Year: 2024

Conclusion

Dr. Hongru Li exemplifies the integration of clinical expertise and research innovation, dedicated to advancing respiratory and cancer medicine through groundbreaking studies, translational discoveries, and compassionate patient care.

Marialuisa Longo | Orthodontics | Best Researcher Award

Dr. Marialuisa Longo | Orthodontics | Best Researcher Award

University of Bari “Aldo Moro” | Italy

Dr. Marialuisa Longo is a dedicated academic and researcher at the University of Bari “Aldo Moro,” specializing in orthodontics and dentistry. Her work integrates both clinical expertise and research-driven innovation, with a strong commitment to enhancing patient care through advanced methodologies and digital tools. Through her contributions, she has helped bridge the gap between traditional orthodontic practices and modern technological approaches. Her scholarly output includes several peer-reviewed journal publications that highlight her impact on improving treatment effectiveness and patient experience. She is an active member of professional organizations such as SIDO, SUSO, and AIDOR, which reflects her commitment to professional development and collaborative knowledge exchange. Dr. Longo’s research and academic endeavors exemplify a balance between theory and practice, making her contributions valuable to both scientific advancement and clinical applications. With a clear vision of advancing dental sciences, she continues to inspire innovation and quality care in orthodontics.

Profile

ORCID

Education

Dr. Marialuisa Longo pursued her academic journey at the University of Bari “Aldo Moro,” where she developed her expertise in dentistry and orthodontics. Her education was marked by rigorous training in both theoretical knowledge and practical applications, equipping her with the skills necessary to excel in academic and clinical practice. The curriculum emphasized an interdisciplinary approach, fostering her understanding of advanced orthodontic methodologies, patient-centered care, and integration of emerging technologies into dental practice. Throughout her education, Dr. Longo was actively involved in research-oriented learning, which laid the foundation for her later scholarly contributions. She demonstrated a strong aptitude for critical thinking, clinical problem-solving, and innovation in dental sciences. Her academic preparation provided her with a comprehensive understanding of the complexities of oral health and orthodontics, shaping her career as both a practitioner and a researcher. The combination of scientific rigor and clinical immersion during her education defines her academic excellence.

Experience

Dr. Marialuisa Longo has cultivated her professional experience at the University of Bari “Aldo Moro,” where she combines academic research, teaching, and clinical practice in dentistry and orthodontics. Her professional journey reflects a dedication to advancing orthodontic treatment through innovative techniques and interdisciplinary collaborations. She has authored several peer-reviewed journal articles that demonstrate her ability to translate scientific knowledge into practical solutions. Her work emphasizes enhancing treatment effectiveness, patient comfort, and the integration of digital tools into modern orthodontic practice. Through her memberships in professional organizations such as SIDO, SUSO, and AIDOR, Dr. Longo engages with the wider dental community, ensuring her work remains informed by global standards and contemporary developments. Her experience is also characterized by mentoring and contributing to the academic development of students, fostering the next generation of dental professionals. The combination of clinical, research, and academic experience makes her a versatile and impactful contributor to dentistry.

Awards and Honors

Dr. Marialuisa Longo’s academic and professional achievements reflect recognition of her contributions to the field of dentistry and orthodontics. Her published research in peer-reviewed journals showcases her commitment to advancing knowledge and improving clinical practice, earning respect within the scientific community. As an active member of prestigious professional associations such as SIDO, SUSO, and AIDOR, she has gained acknowledgment for her engagement in collaborative research and clinical excellence. While her career is still evolving, the quality and significance of her work demonstrate award-worthy accomplishments in integrating innovative technologies with orthodontic care. Her recognition extends beyond publications to her role as a contributor to the academic and clinical missions of the University of Bari “Aldo Moro.” Her ongoing commitment to excellence, coupled with her dedication to patient-focused research and practice, positions her as a promising and deserving candidate for professional honors and awards within the dental sciences.

Research Focus

Dr. Marialuisa Longo’s research focuses on orthodontics and the development of innovative strategies that improve patient care and clinical efficiency. She is particularly interested in integrating digital tools and advanced technologies into traditional orthodontic practices, making treatments more precise, effective, and comfortable for patients. Her published works highlight her contributions to bridging the gap between clinical methodologies and scientific research, ensuring that innovation is directly applied in real-world practice. By collaborating across disciplines within the University of Bari “Aldo Moro,” she contributes to the adoption of evidence-based techniques that transform orthodontic outcomes. Her focus also extends to improving patient experience, emphasizing comfort and efficiency in treatment protocols. Through active involvement in professional associations, she continually aligns her research with the evolving standards of global dentistry. Dr. Longo’s research represents a blend of academic rigor and clinical practicality, aimed at advancing orthodontics through innovation and patient-centered approaches.

Conclusion

Dr. Marialuisa Longo exemplifies the spirit of innovation and dedication in orthodontics through her research, clinical practice, and academic contributions at the University of Bari “Aldo Moro,” where she continuously strives to integrate modern technologies, enhance patient care, and contribute to the global advancement of dentistry, making her an outstanding candidate for the Best Researcher Award.

Muhammad Saeed | Clinical Research | Best Researcher Award

Dr. Muhammad Saeed | Clinical Research | Best Researcher Award

PRX Research | United States

Dr. Muhammad  Saeed is a highly accomplished physician and clinical research leader with extensive expertise in advancing medical innovation. He has dedicated his career to bridging clinical practice and research, focusing on infectious diseases, chronic illnesses, and novel therapeutics. With a foundation in medicine from Dow Medical College, he progressed to leadership positions in multiple U.S.-based clinical research centers, where he directed diverse clinical trials across infectious diseases, neurology, oncology, cardiology, and respiratory medicine. His contributions extend to both academia and industry, including collaborative work with prestigious global institutions. Dr. Saeed’s scholarly work encompasses book chapters and peer-reviewed publications that highlight his dedication to evidence-based medicine and medical education. Beyond his scientific contributions, he is recognized for mentoring young professionals and promoting ethical research practices. His blend of clinical acumen, research excellence, and leadership has positioned him as a key figure in modern translational research and therapeutic development.

Profile

ORCID

Education

Dr. Muhammad Saeed’s academic journey reflects a commitment to excellence and lifelong learning. He earned his Bachelor of Medicine and Bachelor of Surgery (MBBS) from Dow Medical College, University of Karachi, laying the groundwork for his career in clinical medicine and research. His early training emphasized core competencies in surgery and internal medicine, which provided him with strong clinical insights that continue to inform his research leadership. He later pursued advanced studies at Johns Hopkins University, where he completed a Master of Science, equipping him with rigorous training in epidemiology, clinical trial design, and evidence-based research methodologies. His education also includes formative years at Habib Public School in Karachi, where he achieved GCE O’ Levels under the University of Cambridge Local Examination Syndicate. This broad educational foundation, spanning global institutions of repute, has allowed him to integrate strong clinical skills with research innovation, shaping his role as a physician-scientist and educator.

Experience

Dr. Muhammad Saeed’s professional experience spans diverse roles in clinical medicine and research. He began his medical career as a resident physician at Civil Hospital Karachi, training in surgery and medicine. His early exposure to hospital-based care was complemented by research responsibilities at Aga Khan University Hospital, where he worked as a Clinical Research Associate on infectious diseases and public health projects. Transitioning to the United States, he held leadership positions at Advanced Clinical Research Associates in Plano, HRMD Research in Dallas, and later Dallas Regional Medical Center and PRX Research in Mesquite, where he currently serves as Clinical Research Director. In these roles, he has overseen numerous multicenter, international clinical trials across therapeutic areas including oncology, neurology, cardiology, infectious diseases, and COVID-19. His leadership ensures regulatory compliance, patient safety, and high-quality outcomes in research. This experience highlights his ability to integrate patient care, research innovation, and administrative excellence.

Awards and Honors

Dr. Muhammad Saeed has been recognized for his outstanding contributions to clinical research, academic medicine, and patient-centered healthcare. His work in infectious disease research and clinical trial leadership has earned him respect among peers in both academic and industry settings. He has collaborated with leading researchers globally, resulting in publications and recognition in international medical circles. His co-authored book, What I Wish I Knew Before Medical School, reflects his dedication to mentoring and educating the next generation of healthcare professionals, further enhancing his academic reputation. His chapter contributions to the International Encyclopedia of Public Health positioned him among notable voices in global health. Over his career, he has been acknowledged for his role in advancing therapeutic development, particularly during the COVID-19 pandemic through multiple high-impact trials. These honors reflect not only his scholarly achievements but also his contributions to improving medical care through innovative and ethical clinical research practices

Research Focus

Dr. Muhammad Saeed’s research focus lies at the intersection of clinical innovation and public health. His academic research has addressed infectious diseases, including typhoid detection in children and diabetes risk factors in underserved communities. In industry, he has spearheaded large-scale multicenter clinical trials across diverse therapeutic areas, including cardiology, oncology, neurology, respiratory diseases, and COVID-19. His work emphasizes patient safety, treatment efficacy, and advancing therapeutic options for conditions with high unmet medical needs. He has been deeply involved in clinical trial design, implementation, and analysis, ensuring robust outcomes that translate into better clinical practices. Beyond therapeutic innovation, Dr. Saeed’s work reflects a commitment to advancing methodologies for early disease detection, novel biomarkers, stem-cell based therapies, and cutting-edge treatments for neurodegenerative and chronic illnesses. His research philosophy integrates medical rigor, ethical practice, and translational application, aiming to bring scientific discovery from the research bench directly to patient care with lasting global impact.

 

Publications

Title: Impacts of Ambient Temperatures on Pediatric Anemia in Sub-Saharan Africa: A Regional Ecological Study
Year: 2025

Title: Evaluation of the Potential Of Rejuveinix Plus Dexamethasone Against Sepsis
Year: 2022

Title: Clinical and Non-clinical Proof of Concept Supporting the Development of RJX As an Adjunct to Standard of Care Against Severe COVID-19
Year: 2022

Title: Factors associated with disease severity and mortality among patients with COVID-19: A systematic review and meta-analysis
Year: 2020

Title: Clinical characteristics, management and outcome of major pulmonary embolism: an experience from a tertiary care center in Pakistan
Year: 2009

Conclusion

Dr. Muhammad  Saeed is a distinguished physician-scientist whose career blends clinical expertise, research leadership, and academic scholarship, with a strong focus on advancing therapeutic innovation, improving patient care, and mentoring future medical professionals through global collaborations and ethical research excellence.

Milena Živković | Artificial Intelligence in Medicine | Best Researcher Award

Ms. Milena Živković | Artificial Intelligence in Medicine | Best Researcher Award

Research Associate| University of Kragujevac, Faculty of Science, Serbia

Milena Živković is a Research Associate at the University of Kragujevac, Faculty of Science, Serbia, with a background in physics and a research focus on the integration of artificial intelligence into medical physics and science education. Her expertise lies in AI-supported educational systems, Monte Carlo simulations in radiotherapy, and environmental radioactivity. With over 38 published papers, her work bridges physics, machine learning, and curriculum innovation. Milena is recognized for her mentorship of gifted students, contribution to interdisciplinary AI-based learning models, and international collaborations with researchers in Europe and the Middle East. She has co-authored dosimetric simulation software for cancer treatment optimization and earned accolades such as Best Oral Presentation Awards at international conferences. As an active member of the Serbian and German Physical Societies, she fosters science communication through national outreach projects and educational initiatives. Her contributions span both academic excellence and impactful community-based science promotion efforts.

Profile

🎓 Education

Milena Živković earned her formal education in physics, culminating in specialized research focused on medical physics, radiation dosimetry, and educational technology. She has completed advanced academic training in English for Academic Communication and Python programming, including Stanford’s “Code in Place.” She holds a Cambridge English Certificate and multiple certificates from the University of Kragujevac in academic writing and pedagogy. Her achievements during her student years include receiving the Annual Award for Best Student from 2015 to 2019, reflecting both academic excellence and extracurricular engagement. Additionally, she has participated in numerous interdisciplinary workshops, competitions, and science communication events, contributing to both her intellectual and pedagogical growth. With a strong foundation in applied physics, her academic journey has been characterized by the seamless integration of theoretical knowledge and practical research, which she continues to expand through post-academic training, conference participation, and interdisciplinary research collaboration with clinical and educational institutions.

🧪 Experience

Milena Živković has significant experience as a Research Associate at the University of Kragujevac, where she combines artificial intelligence with physics education and medical applications. Her research includes machine learning models for radiation dosimetry, classification systems in physics education, and anomaly detection in environmental radioactivity. She serves as a section editor and reviewer for journals like Imaging and Radiation Research and Radiation Science and Technology. Milena is also a contributor to national gifted education programs, curriculum development initiatives, and AI-assisted learning models. She has collaborated with international institutions, including projects with the Clinical Center Kragujevac and partners from Iraq, enhancing the practical application of her research. She has guided STEM projects for youth and mentored students in high school competitions. Her book on Monte Carlo simulations is used in academic and clinical contexts. Her scientific outreach projects further amplify her impact across the academic, educational, and public spheres.

🏅 Awards and Honors

Milena Živković has been the recipient of numerous awards recognizing both academic and community contributions. She received the Best Researcher Award at the University of Kragujevac in 2023 and multiple Best Oral Presentation Awards at international conferences in gynecology, women’s health, and ophthalmology. She also won the Bridge of Mathematics First Place Projects (2023, 2024), highlighting innovative physics education. From 2015 to 2019, she was honored with the Annual Best Student Award and continues to receive high praise for promoting science through projects funded by Serbia’s Center for the Promotion of Science. These include thematic campaigns like Brian May and the Queen of Physics, Our Air = Our Health, and Work + Active = Radioactive. Additionally, she holds advanced training certifications in pedagogy, communication, academic writing, and programming. Her dedication to science communication, youth mentorship, and educational innovation has made her a strong contender for the Young Scientist or Best Researcher Award.

🔬 Research Focus

Milena Živković’s research sits at the intersection of artificial intelligence, medical physics, and education technology. She focuses on developing machine learning-based models for radiation dose analysis, anomaly detection in environmental radioactivity, and AI-assisted problem classification in physics education. Her contributions to the FOTELP-VOX Monte Carlo platform enable precision 3D dose distribution modeling, now applied in clinical settings. She also investigates the ecological effects of radionuclide transfer and food safety. Milena’s interdisciplinary work includes collaborations with philosophers, clinicians, educators, and AI developers to improve curriculum delivery and treatment outcomes. She actively integrates AI into educational strategies to support gifted students and has co-authored software tools used in radiotherapy optimization. Her studies are not only technical but are aimed at real-world impact—ensuring safer radiation practices, informed public health strategies, and accessible science education. Her research promotes knowledge translation, making complex physics applicable to both education and healthcare.

Conclusion

Milena Živković exemplifies a new generation of researchers merging artificial intelligence with applied physics to transform education, healthcare, and science communication. Through interdisciplinary projects, academic excellence, and outreach initiatives, she continues to redefine how science serves society while mentoring future innovators and advancing clinical safety and educational equity.

Publications
  • FOTELP-VOX-OA: Enhancing radiotherapy planning precision with particle transport simulations and Optimization Algorithms

    Computer Methods and Programs in Biomedicine
    2025-08 | Journal article
    CONTRIBUTORS: Milena Zivkovic; Filip Andric; Marina Svicevic; Dragana Krstic; Lazar Krstic; Bogdan Pirkovic; Tatjana Miladinovic; Mohamed El Amin Aichouche
  • FOTELP-VOX 2024: Comprehensive overview of its capabilities and applications

    Nuclear Technology and Radiation Protection
    2024 | Journal article
    CONTRIBUTORS: Milena Zivkovic, P.; Tatjana Miladinovic, B.; Zeljko Cimbaljevic, M.; Mohamed Aichouche, E.A.; Bogdan Pirkovic, A.; Dragana Krstic, Z.
  • Radionuclide contamination in agricultural and urban ecosystems: A study of soil, plant, and milk samples

    Kragujevac Journal of Science
    2024 | Journal article
    CONTRIBUTORS: Mohamed Aichouche, E.A.; Mihajlo Petrović, V.; Milena Živković, P.; Dragana Krstić, Ž.; Snežana Branković, R.
  • Development of DynamicMC for PHITS Monte Carlo package

    Radiation Protection Dosimetry
    2023-11-13 | Journal article
    Part of ISSN: 0144-8420
    Part of ISSN: 1742-3406
    CONTRIBUTORS: Hiroshi Watabe; Tatsuhiko Sato; Kwan Ngok Yu; Milena Zivkovic; Dragana Krstic; Dragoslav Nikezic; Kyeong Min Kim; Taiga Yamaya; Naoki Kawachi; Hiroki Tanaka et al.

Ejaz Ahmad Khera | Materials Simulation | Best Researcher Award

Dr. Ejaz Ahmad Khera | Materials Simulation | Best Researcher Award


Dr. Ejaz Ahmad Khera is an Assistant Professor of Physics at The Islamia University of Bahawalpur, Pakistan, and an HEC-approved supervisor with a PhD in the characterization of materials for memory storage and neuromorphic applications using DFT. He has published over 30 high-impact international research articles and currently leads research at the Materials Modeling and Simulation Lab, where he supervises MPhil and PhD students. His group is actively involved in developing efficient double perovskites for solar cell applications. In addition to his academic and research roles, Dr. Khera contributes to departmental administrative functions and has participated in multiple international conferences in physics and materials science. He is proficient in VASP, Wien2k, CASTEP, and other computational tools, reflecting his strong background in computational materials physics.

Profile

Education 🎓

Dr. Khera earned his PhD in Physics from The Islamia University of Bahawalpur (2016–2021), focusing on DFT-based characterization of materials for neuromorphic and memory applications. He holds an MPhil in Physics from Allama Iqbal Open University, Islamabad (2012–2014), and a Master of Science in Physics from Bahauddin Zakariya University, Multan (2007–2010). His academic foundation combines theoretical physics, computational modeling, and practical understanding of solid-state and condensed matter systems. He is trained in multiple simulation platforms including VASP, Wein2k, and CASTEP, and has built expertise in data analysis software like Origin and visualization tools like VESTA and Crystal Maker. His solid academic training has enabled him to mentor graduate students in computational material science and renewable energy research domains. Dr. Khera has also enhanced his academic exposure through participation in pedagogical and research methodology training programs.

Experience 👨‍🏫

Dr. Khera is currently serving as Assistant Professor of Physics at The Islamia University of Bahawalpur since March 2022, where he teaches undergraduate and postgraduate courses, leads research, and manages academic administration. From 2019 to 2021, he was a visiting lecturer at University of Education, Multan Campus, and previously taught physics at Admire Group of Colleges (2017–2021), Muslim Group of Colleges (2013–2017), and Educators Group of Colleges (2011–2013), focusing on undergraduate and higher secondary education. Over a decade of teaching experience has honed his expertise in delivering core physics concepts and mentoring students. In his academic tenure, Dr. Khera has also built research collaborations and guided MPhil and PhD students in materials modeling. His responsibilities have included curriculum design, academic planning, and seminar coordination. He is deeply engaged in academic development through active participation in physics conferences and workshops.

Awards & Recognitions 🏅

Dr. Khera received the Prime Minister Youth Laptop Scheme award from the Federal Government of Pakistan in 2018, recognizing his academic excellence and contribution to higher education. He was also granted the Punjab Government Scholarship under the Fee Reimbursement Scheme for Higher Education in 2017, awarded by the Government of Punjab. These honors reflect his academic merit, commitment to research, and service in the field of physics education. He has participated in multiple international and national-level conferences, including events hosted by The Islamia University of Bahawalpur and The Women University Multan. His consistent performance in academics and his role in teaching and research supervision have earned him institutional recognition. Additionally, his HEC-approved supervisor status further signifies his qualification and leadership in guiding advanced research projects in Pakistan. These accolades support his active involvement in national education development and scientific advancement in materials science.

Research Interests 🔬

Dr. Khera’s research is centered on computational materials science with a focus on density functional theory (DFT)-based investigations of electronic, optical, thermoelectric, and structural properties of novel materials. His primary interest lies in characterizing double perovskites (DPs), Heusler alloys, and vacancy-ordered compounds for use in solar cells, memory storage, brain-inspired neuromorphic systems, and energy harvesting applications. Using simulation tools like VASP, CASTEP, and Wien2k, he studies materials such as Ga₂PtX₆, Li₂ATlCl₆, and Na₂PtX₆ for their optoelectronic and thermoelectric performance. His recent publications explore halogen modification, spin polarization, and hybrid perovskites for sustainable technologies. His research group actively contributes to discovering lead-free, high-efficiency materials that align with global goals for clean and renewable energy. Dr. Khera also collaborates internationally, co-authoring papers with scientists across Asia and Europe, thereby advancing the field of computational physics and sustainable material development.

Publications

 

  • Probing the opto-electronic, thermoelectric, thermodynamic and elastic responses
    of lead-free double perovskite Li2ATlCl6 (A= Na and K) for potential photovoltaic
    and high-energy applications: A DFT study
    Reference: Qiguo Xiao, Abrar Nazir, Ejaz Ahmad Khera, Mumtaz Manzoor, Ramesh
    Sharma, Javed Rahman, Sabah Ansar, Farooq Ali
    Link: https://www.sciencedirect.com/science/article/pii/S0921510724006895

 

  • First principles investigation of structural, electronic, optical, transport properties
    of double perovskites X2TaTbO6 (X= Ca, Sr, Ba) for optoelectronic and energy
    harvesting applications
    Reference: Mudassir Ishfaq, Muniba Urooj, Muhammad Sajid, Khawar Ismail, Rimsha
    Baqeel, Ejaz Ahmad Khera, Rajwali Khan, Sattam Al Otaibi, Khaled Althubeiti, Hassan Ali,
    Ghulam Murtaza, Muhammad Jamil
    Link: https://www.sciencedirect.com/science/article/pii/S0022369724005675

 

 

Nathan Robert Wall | Medicine | Excellence in Research Award

Dr. Nathan Robert Wall | Medicine | Excellence in Research Award

Dr. Nathan R. Wall is an accomplished academic, biomedical researcher, and military officer. He is currently an Associate Professor of Medicine at Loma Linda University School of Medicine and holds multiple leadership roles in research, oncology education, and national defense. With advanced degrees in biology, cancer biology, and business administration, he has dedicated his career to cancer research and military medical operations. Dr. Wall has served in multiple deployments with the California Army National Guard, including missions in Afghanistan, Poland, and Iraq. His military and academic excellence is recognized through numerous awards and honors. Dr. Wall combines rigorous research in molecular medicine with a passion for leadership, education, and national service. His extensive experience in academia, clinical research, and military command uniquely positions him at the intersection of science and strategic operations, contributing to both medical advancement and national security.

Profile

Education 🎓

Dr. Nathan R. Wall is currently pursuing a Master of Strategic Studies at the U.S. Army War College (2024–2026). He earned his MBA with a focus in Management from the University of Redlands (2006–2008), and a Ph.D. in Cancer Biology from Wayne State University (1996–2000), where he also completed an M.S. in Molecular Biology and Genetics. Prior to that, he obtained an M.S. in Biology (1992–1995) and a B.S. in Biology with a minor in Chemistry (1987–1991) from Walla Walla College (now Walla Walla University). His graduate training included mentorship under leading scientists like Dr. Ayad M. Al-Katib and Dr. Joan M. Redd. Across disciplines—from molecular biology to strategic leadership—Dr. Wall’s education reflects a commitment to interdisciplinary excellence, equipping him with the skills to navigate both biomedical research and complex military operations with strategic insight.

Experience 👨‍🏫

Dr. Nathan R. Wall has held academic appointments at Loma Linda University since 2008, currently serving as Associate Professor of Medicine in the Division of Human Anatomy. He also directs Research and Development at the James M. Slater Proton Treatment & Research Center and is Oncology Thread Director at the School of Medicine. Previously, he served in the Department of Biochemistry and Center for Health Disparities. Since 2008, Dr. Wall has simultaneously served in the California Army National Guard, rising through the ranks and completing deployments to Afghanistan, Poland, and Iraq in key command roles. He has also contributed as a scientific advisor for biotech firms and participated in Department of Defense medical research review panels. His interdisciplinary experience spans military medicine, molecular oncology, academic leadership, and national defense, making him a unique leader who bridges science, strategy, and service.

Awards & Recognitions 🏅

Dr. Wall’s exemplary service has earned him numerous military and civilian accolades. These include the Bronze Star Medal, NATO Medal, Afghanistan Campaign Medal, Global War on Terrorism Service Medal, and the Honorable Order of Saint Martin. He’s received multiple Army Commendation and Achievement Medals, along with California-specific honors like the California Medal of Merit and Drill Attendance Ribbon with multiple stars. Notably, he was recognized as “Citizen Warrior of the Month” by California ARNG Magazine in August 2018. Dr. Wall has also been honored with plaques and certificates from NATO, Bulgarian Joint Forces, and various military medical programs. His academic achievements include tenure at Loma Linda University and leadership roles in key training inspections. These honors reflect his unwavering commitment to excellence, leadership in medical readiness, and profound impact in both academic and military sectors.

Research Interests 🔬

Dr. Wall’s research focuses on cancer biology, with specific expertise in molecular mechanisms of disease, targeted therapies, and translational oncology. His work bridges basic science and clinical application, especially in the context of proton therapy and health disparities in underserved populations. At Loma Linda University, he leads interdisciplinary teams addressing tumor microenvironments, cancer signaling pathways, and innovative therapeutics. Dr. Wall also contributes to Department of Defense research as a peer reviewer, ensuring scientific rigor in funded medical studies. His research often integrates his military background, exploring how stress and trauma-related factors influence cancer biology and immune responses. As Director of R&D at a leading proton treatment center, he’s advancing precision medicine in oncology. Dr. Wall’s work is marked by its practical implications, scientific depth, and commitment to improving patient care—particularly for populations affected by health inequities or involved in military service.

Publications
  • Seco-Duocarmycin SA in Aggressive Glioblastoma Cell Lines

    International Journal of Molecular Sciences
    2025-03-19 | Journal article
    CONTRIBUTORS: Ann Morcos; Yeonkyu Jung; Ryan N. Fuller; Antonella Bertucci; Amy Nguyen; Quanqing Zhang; Tobias Emge; Kristopher E. Boyle; Nathan R. Wall; Marcelo Vazquez
  • A Comprehensive Review of the Antitumor Properties and Mechanistic Insights of Duocarmycin Analogs

    Cancers
    2024-09-27 | Journal article
    CONTRIBUTORS: Ann Morcos; Yeonkyu Jung; Joab Galvan Bustillos; Ryan N. Fuller; David Caba Molina; Antonella Bertucci; Kristopher E. Boyle; Marcelo E. Vazquez; Nathan R. Wal
  • A CTB-SARS-CoV-2-ACE-2 RBD Mucosal Vaccine Protects Against Coronavirus Infection

    Vaccines
    2023-12-18 | Journal article
    CONTRIBUTORS: Béla Dénes; Ryan Fuller; Wayne Kelin; Tessa Levin; Jaipuneet Gil; Aaren Harewood; Márta Lőrincz; Nathan Wall; Anthony Firek; William Langridg

Jim Jinn-Chyuan Sheu | Precision medicine | Best Researcher Award

Dr. Jim Jinn-Chyuan Sheu | Precision medicine | Best Researcher Award

Dr. Jim Jinn-Chyuan Sheu is a professor at the Institute of Biomedical Sciences, National Sun Yat-sen University, Taiwan, and an adjunct professor in several prestigious institutions. With a PhD in Life Science from National Tsing-Hua University, his academic and industrial experiences span cancer genetics, precision medicine, and biopharmaceuticals. He has held positions at Johns Hopkins Medical Institutions and Development Center for Biotechnology. His research explores molecular mechanisms underlying diseases such as cancer and endometriosis, employing genome-wide technologies to identify biomarkers and drug targets. He actively contributes to biomedical innovation, translational medicine, and mentorship. Dr. Sheu has received numerous national and international awards, including the Wu-Da-You Memorial Award and Sigma Xi membership. He is also an ambassador for the European Association for Cancer Research. As a prolific researcher and reviewer, he plays key roles in research councils and institutional review boards, helping shape scientific policy and translational biomedical advancements in Taiwan and beyond.

Profile

Education 🎓

Dr. Sheu earned his Ph.D. in Life Science from National Tsing-Hua University, Taiwan, in 2002, where he focused on advanced molecular biology, gene expression regulation, and biomedical research. His doctoral training provided a strong foundation in cancer genetics and systems biology. Earlier, he completed his B.S. in Biology (now Life Science) from Fu-Jen University in 1994, building core competencies in biological sciences and cellular mechanisms. These educational milestones equipped him with theoretical knowledge and technical skills in genomics, proteomics, and cellular signaling, which are now reflected in his research on chromatin remodeling, cancer biomarkers, and therapeutic targets. Through rigorous academic mentorship, Dr. Sheu gained early exposure to multidisciplinary research and critical analysis, fostering his interest in precision medicine. His academic background laid the groundwork for his contributions to biomedical research, drug development, and translational science. These formative years in Taiwan’s top universities underpin his long-standing excellence in scientific discovery and innovation.

Experience 👨‍🏫

Dr. Sheu’s professional experience includes faculty roles and research leadership across academia and industry. He has served as a Professor at National Sun Yat-sen University since 2014 and previously held faculty roles at China Medical University. Internationally, he was a Research Fellow at Johns Hopkins Medical Institutions (2004–2006). Between 2003–2004, he worked in various leadership positions at the Development Center for Biotechnology, including Director of Protein Drugs Division and Project Leader. His postdoctoral and early research roles included work with Dr. Tse-Wen Chang and Dr. Carmay Lim at Academia Sinica. His academic leadership includes roles such as Associate VP of R&D, Chair of the Institute of Biomedical Sciences, and Director of Research Resources at NSYSU. He has reviewed research proposals for numerous hospitals and institutions, served on IRBs, and guided government research policy. His diverse experience bridges basic science, translational research, and biomedical entrepreneurship with national and global impact.

Awards & Recognitions 🏅

Dr. Sheu has received over 30 prestigious awards. In 2023 alone, he earned the Tien-Te Lee Award, NSYSU Outstanding Faculty Award, and top honors at the 37th Joint Biomedical Conference. He previously received the Prof. Chii-Ruey Tzeng Award, Sigma Xi membership (2021), and EACR Ambassador role (2020). His innovation was recognized by Future Tech Award and the 2020 Smart Life Innovation Competition. His studies were featured as Taiwan Research Highlights and F1000Prime recommendations. He was the 2014 recipient of the Wu-Da-You Memorial Award and the IBC Outstanding Scientific Achievement Award. He received the Medical Young Investigator Award in 2009 and the Best Basic Science Award at Johns Hopkins in 2005. As a government-financed scholar to the U.S., his academic excellence has been internationally recognized. He consistently ranks among Taiwan’s top biomedical researchers, illustrating his impact through award-winning research in endometriosis, cancer stemness, diagnostics, and therapeutic innovation.

Research Interests 🔬

Dr. Sheu’s research focuses on cancer genetics and genomics, endometriosis, precision medicine, chromatin remodeling, cytoskeletal dynamics, cell adhesion and invasion, and mechanotransduction. His lab investigates how abnormalities in gene expression and chromatin structure drive disease progression, especially in gynecologic cancers and endometriosis. By applying genome-wide analysis and bioinformatics, his team identifies disease-driving genes and develops novel diagnostic tools and therapeutic strategies. A key interest is the tumor microenvironment and how cytoskeletal networks and nuclear architecture influence cancer stemness and metastasis. His group explores traditional Chinese medicine compounds and stem cell therapies, advancing integrative approaches to medicine. Antibody and vaccine engineering are also integral to his translational pipeline. Funded by NSTC Taiwan and other institutions, his projects target non-invasive diagnostics and biomarker-based interventions. His long-term vision involves bridging molecular biology, clinical application, and therapeutic innovation to impact patient care and global health through interdisciplinary and precision-driven biomedical science.

Publications

Fan Zhang | Proteomics | Best Researcher Award

Dr. Fan Zhang | Proteomics | Best Researcher Award

Fan Zhang, born on September 23, 1991, is a postdoctoral researcher specializing in cancer proteogenomics 🔬. He is currently with the Department of Pathology at Duke University 🏛️. His research leverages mass spectrometry and bioinformatics 🖥️ to investigate metabolic pathways in therapy-resistant prostate cancer and other malignancies. He has received the FY23 Prostate Cancer Research Program Early Investigator Research Award 🏆 for his work on glutamine metabolism in advanced prostate cancer. His contributions to proteogenomics have resulted in multiple high-impact publications 📄 in Nature Communications, Cell Research, and Molecular & Cellular Proteomics. Proficient in LC-MS/MS, bioinformatics analysis, and experimental techniques, his research bridges the gap between basic cancer biology and clinical applications 🏥, paving the way for novel therapeutic strategies in oncology.

Profile

Education 🎓

Fan Zhang holds a Ph.D. in Biochemistry and Molecular Biology from Fudan University (2015-2020), where he focused on proteogenomic research. He further pursued postdoctoral training in Clinical Medicine at Fudan University (2020-2022) before joining Duke University as a postdoctoral researcher in the Department of Pathology in 2023. His academic journey began with a B.S. in Applied Biological Science from Anhui Agricultural University (2011-2015). Throughout his education, he gained expertise in genomics, transcriptomics, and proteomics, developing a strong foundation in bioinformatics and experimental methodologies. His interdisciplinary training has equipped him with skills in mass spectrometry-based proteomics, omics data analysis, and cancer metabolism research. His current research at Duke University focuses on metabolic vulnerabilities in prostate cancer, aiming to develop targeted therapies. His diverse academic background enables him to integrate various scientific disciplines, contributing significantly to cancer research and precision medicine.

Experience 👨‍🏫

Fan Zhang has extensive research experience in cancer proteogenomics. Currently a postdoctoral researcher at Duke University (2023-present), he investigates metabolic vulnerabilities in prostate cancer using advanced mass spectrometry and omics analysis. Previously, he was a postdoc in Clinical Medicine at Fudan University (2020-2022), where he contributed to proteogenomic studies on various cancers, including pituitary neuroendocrine tumors and diffuse large B-cell lymphoma. His Ph.D. at Fudan University (2015-2020) focused on proteogenomic characterizations of cancer, leading to high-impact publications. He is proficient in LC-MS/MS, bioinformatics, and experimental methodologies such as Western blotting, immunofluorescence, and cell culture. His research integrates mass spectrometry with genomics and transcriptomics to uncover novel therapeutic targets. With expertise in multi-omics data analysis, he has significantly contributed to the field of cancer biology. His work is supported by prestigious grants, highlighting his role as a leading researcher in proteogenomics and precision oncology.

Research Interests 🔬

Fan Zhang’s research focuses on proteogenomics and cancer metabolism, particularly in therapy-resistant malignancies like prostate cancer, pituitary neuroendocrine tumors, and diffuse large B-cell lymphoma. He specializes in mass spectrometry-based proteomics (DDA, DIA) and integrates multi-omics approaches, including genomics, transcriptomics, and metabolomics, to uncover novel cancer vulnerabilities. His current work at Duke University investigates glutamine metabolism in castration-resistant prostate cancer, aiming to develop targeted therapies. His expertise extends to bioinformatics analysis, large-cohort omics data interpretation, and advanced LC-MS/MS techniques for various biological samples. His research has led to multiple high-impact publications, highlighting his ability to translate complex molecular data into potential clinical applications. By combining experimental and computational approaches, he aims to identify biomarkers and therapeutic targets that can improve cancer treatment. His contributions to proteogenomics play a crucial role in advancing precision oncology and understanding the metabolic reprogramming of aggressive cancers.

 

Awards & Recognitions 🏅

Fan Zhang has received multiple awards and recognitions for his contributions to cancer proteogenomics. He was awarded the Fiscal Year 2023 (FY23) Prostate Cancer Research Program (PCRP) Early Investigator Research Award (2023-2025) for his project on targeting glutamine metabolism in advanced prostate cancer (Award Number HT9425-24-1-0237). His research has been recognized through multiple first-author and co-first-author publications in high-impact journals such as Nature Communications, Molecular & Cellular Proteomics, Cell Research, and The Prostate. His work has also been featured as a cover article in Cell Research (2022). His expertise in mass spectrometry, proteogenomics, and bioinformatics has positioned him as a leading young investigator in the field. In addition to research grants, he has received accolades for his innovative contributions to metabolic studies in oncology. His commitment to advancing cancer research has been instrumental in developing novel therapeutic strategies for therapy-resistant malignancies.

Publications 📚

Natalia Baran | Cancer Research | Best Researcher Award

Assist. Prof. Dr. Natalia Baran | Cancer Research | Best Researcher Award

Leading Attending at InselSpital Bern, Switzerland.

Dr. Natalia Baran is an Assistant Professor in the Department of Leukemia at MD Anderson Cancer Center, where she focuses on developing novel therapeutic strategies targeting metabolic vulnerabilities in leukemia. Her expertise lies in understanding how metabolic reprogramming can lead to drug resistance and contribute to leukemia progression. With a medical background and extensive experience in both clinical and research settings, Dr. Baran has been at the forefront of studies that aim to modulate metabolic pathways to enhance anti-leukemic responses. By combining insights from molecular biology, immunology, and clinical practice, she is actively working toward discovering innovative treatments for leukemia. Dr. Baran’s research holds great promise in advancing leukemia therapy, particularly by targeting metabolic reprogramming in the context of therapy resistance. Her multidisciplinary approach, integrating clinical data with laboratory research, makes her a key figure in leukemia research.

Profile

Scopus

Google Scholar

Orcid

Education:

Dr. Natalia Baran completed her undergraduate studies in Biotechnology, earning a Master of Science degree in 2006 from Wroclaw University of Science and Technology in Poland. She further pursued medical education and obtained her Medical Doctor (MD) degree from Wroclaw Medical University in 2007. Driven by her passion for research, Dr. Baran earned a Ph.D. in Medicine from the University of Bonn in 2015. Her doctoral research laid the foundation for her current focus on leukemia and metabolic reprogramming. In addition, Dr. Baran underwent extensive postdoctoral training at MD Anderson Cancer Center, where she honed her expertise in hematology and oncology, contributing significantly to translational research in leukemia. Her diverse educational background, blending science and medicine, has shaped her comprehensive approach to cancer research.

Professional Experience:

Dr. Baran has a rich professional experience that bridges clinical practice and cutting-edge research. After completing her MD, she pursued clinical residencies in Internal Medicine, Hematology, and Oncology at prestigious German institutions, including the University of Heidelberg and the University of Bonn. This clinical experience laid the groundwork for her subsequent focus on leukemia research. In 2016, she joined MD Anderson Cancer Center as a Postdoctoral Fellow in the Department of Leukemia. During her postdoctoral tenure, Dr. Baran worked closely with Dr. Marina Konopleva, exploring the role of metabolic pathways in leukemia resistance. By 2022, she had transitioned to an Assistant Professor role, continuing her translational research in leukemia, with a particular emphasis on identifying novel therapeutic strategies. Her clinical and research experiences synergize to enhance her contributions to the leukemia research community.

Research Interests:

Dr. Baran’s research is primarily centered on exploring metabolic vulnerabilities and their role in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Her work seeks to understand the mechanisms through which metabolic reprogramming in leukemia cells contributes to drug resistance and tumor progression. Dr. Baran is particularly interested in how modulating the metabolic environment can enhance the effectiveness of leukemia therapies. By focusing on the interplay between metabolism and leukemic cell survival, she aims to identify new therapeutic strategies that target metabolic pathways to overcome resistance to traditional treatments. Her research also explores how immune modulation can be integrated with metabolic interventions to develop more efficient leukemia therapies.

Awards and Honors:

Dr. Baran has received recognition for her contributions to leukemia research, although specific awards are not detailed in available sources. However, her research has been featured prominently in major scientific forums, including the Annual Metabolism in Cancer Symposium organized by MD Anderson. Her work has earned her respect within the scientific community, as evidenced by her continued role as an Assistant Professor and her involvement in prestigious cancer research initiatives. Dr. Baran’s impact is evident in her ongoing efforts to bridge the gap between basic science and clinical application, aiming to revolutionize leukemia treatment.

Skills:

Dr. Baran’s research skills encompass a wide range of techniques in molecular biology, cell culture, and metabolic analysis. She is highly proficient in studying the metabolic pathways that drive leukemia, using state-of-the-art technologies such as high-resolution metabolic flux analysis, RNA sequencing, and advanced cell imaging. Dr. Baran is skilled at integrating basic science with clinical data, ensuring that her research translates into practical therapeutic interventions. Her expertise in immunology further complements her research in leukemia, allowing her to investigate the potential of combining metabolic therapies with immune modulation to improve patient outcomes. Her interdisciplinary approach is a key strength in her ongoing work in leukemia research.

Publication Top Notes

A Selective BCL-XL PROTAC Degrader Achieves Safe and Potent Antitumor Activity

  • Authors: S Khan, X Zhang, D Lv, Q Zhang, Y He, P Zhang, X Liu, D Thummuri, et al.
  • Journal: Nature Medicine
  • Volume: 25(12), Pages 1938–1947
  • Cited by: 515
  • Year: 2019

Targeting a Cytokine Checkpoint Enhances the Fitness of Armored Cord Blood CAR-NK Cells

  • Authors: M Daher, R Basar, E Gokdemir, N Baran, N Uprety, AK Nunez Cortes, et al.
  • Journal: Blood, The Journal of the American Society of Hematology
  • Volume: 137(5), Pages 624–636
  • Cited by: 226
  • Year: 2021

Inhibiting Glutaminase in Acute Myeloid Leukemia: Metabolic Dependency of Selected AML Subtypes

  • Authors: P Matre, J Velez, R Jacamo, Y Qi, X Su, T Cai, SM Chan, A Lodi, et al.
  • Journal: Oncotarget
  • Volume: 7(48), Pages 79722
  • Cited by: 194
  • Year: 2016

Complex I Inhibitor of Oxidative Phosphorylation in Advanced Solid Tumors and Acute Myeloid Leukemia: Phase I Trials

  • Authors: TA Yap, N Daver, M Mahendra, J Zhang, C Kamiya-Matsuoka, et al.
  • Journal: Nature Medicine
  • Volume: 29(1), Pages 115–126
  • Cited by: 182
  • Year: 2023

Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy

  • Authors: N Baran, M Konopleva
  • Journal: Clinical Cancer Research
  • Volume: 23(10), Pages 2382–2390
  • Cited by: 126
  • Year: 2017

Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-Like Responses Against CD30+ Malignancies

  • Authors: LN Kerbauy, ND Marin, M Kaplan, PP Banerjee, MM Berrien-Elliott, et al.
  • Journal: Clinical Cancer Research
  • Volume: 27(13), Pages 3744–3756
  • Cited by: 117
  • Year: 2021

Clonal Selection and Therapy Resistance in Acute Leukemias: Mathematical Modelling Explains Different Proliferation Patterns at Diagnosis and Relapse

  • Authors: T Stiehl, N Baran, AD Ho, A Marciniak-Czochra
  • Journal: Journal of The Royal Society Interface
  • Volume: 11(94), Article ID 20140079
  • Cited by: 106
  • Year: 2014

Activation of RAS/MAPK Pathway Confers MCL-1 Mediated Acquired Resistance to BCL-2 Inhibitor Venetoclax in Acute Myeloid Leukemia

  • Authors: Q Zhang, B Riley-Gillis, L Han, Y Jia, A Lodi, H Zhang, S Ganesan, R Pan, et al.
  • Journal: Signal Transduction and Targeted Therapy
  • Volume: 7(1), Article ID 51
  • Cited by: 104
  • Year: 2022

Conclusion:

Dr. Natalia Baran is a prominent researcher whose work in leukemia has the potential to transform therapeutic approaches, especially through targeting metabolic pathways. Her strong academic background, combined with extensive clinical and research experience, enables her to address one of the most pressing challenges in leukemia treatment: drug resistance. By focusing on metabolic reprogramming, Dr. Baran is paving the way for innovative strategies to combat leukemia and improve patient outcomes. Her expertise in integrating basic research with clinical applications ensures that her contributions will have a lasting impact on the field of oncology, particularly in the development of new, more effective therapies for leukemia.